Impact of anti-cancer treatments on outcomes of COVID-19 in patients with thoracic cancers: a CCC19 registry analysis [Apr 10, 2024] Kulkarni et al. Narjust Florez, MD, FASCO COVID-19 and Cancer Consortium (CCC19) Registry Clinical Lung Cancer
clinical-lung-cancer.com/article/S1525-… #COVID19 nCancer #COVID19 #lcsm

The treatment landscape of neoadjuvant/perioperative immunotherapy for NSCLC is rapidly evolving.

Check out a review article that highlights key outcomes from major clinical trials and identifies current knowledge gaps.

bit.ly/4dDOp3H

Matched pair cohort study of #EGFR NSCLC Clinical Lung Cancer again shows that if PD(L)1 inhibitors are given before EGFR TKIs, higher risk of pneumonitis and higher in-hospital mortality. Seen with various EGFR TKIs. Reminder to wait for biomarker results!
clinical-lung-cancer.com/article/S1525-…

Explore a recent article that describes the differences between TMB, neoantigen load, PD-L1, CD4, and NK cell proportions according to MET mutation or amplification status.

bit.ly/44C61J4

Check an article on patients who completed two years of #pembrolizumab for advanced NSCLC, highlighting high rates of KRAS mutation & PD-L1 expression, and a subset with brain metastases and treated oligoprogression.

Full article: bit.ly/3Qz1FNa

1/ 🔥Our 🆕 Clinical Lung Cancer Brief Report on 1L testing & management in mNSCLC is out! With multiple frontline treatments, it's a complex landscape!

Enjoyed collaborating w/ mentee Arthi Sridhar & mentor H. Jack West, MD.

Key insights👇🏽, a 🧵: ⁦OncoAlert⁩ sciencedirect.com/science/articl…

Updated outcomes from phase II Chinese study of lorlatinib 100mg qday in previously treated #ALK NSCLC Clinical Lung Cancer. PFS post crizotinib was 26.3m. PFS after other ALK TKIs was 5.6m. No new safety signals with longer 3y f/u.

clinical-lung-cancer.com/article/S1525-…

Certainly confounders here, but interesting look at immediate vs deferred systemic therapy in pts with pleural mesothelioma Clinical Lung Cancer. In this group, 58% of deferred pts eventually had systemic therapy. OS longer in deferred group (20.6m vs 11.5m).

clinical-lung-cancer.com/article/S1525-…

Novel EGFR germline mutation in an individual with lung cancer. Germline mutations in lung cancer is a developing paradigm with the potential to change screening guidelines.

Himil Mahadevia Janakiraman Subramanian Saint Luke's Cancer Institute Ben Ponvilawan Clinical Lung Cancer

clinical-lung-cancer.com/article/S1525-…

🔥COPILOT: Completion Of Pembrolizumab In advanced NSCLC
🎙️Dr. A Fantoni Clinical Lung Cancer
🎯Real world Outcomes after Two years of therapy ()
✅Observational study
✅Primary: PFS
✅AUstralian Registry and biObank of thoRacic cAncers (AURORA)
#LCSM OncoAlert
clinical-lung-cancer.com/article/S1525-…

Real world description of pts who completed 2y of 1L pembrolizumab Clinical Lung Cancer (n=71). In this group, RR 79%, mPFS 46.1m, 60% with #KRAS mt. 24% received local ablation for oligoprogression. 28% progressed after stopping pembro (more if PDL1 < 1%).

clinical-lung-cancer.com/article/S1525-…

A review published in Clinical Lung Cancer provides a comprehensive summary of published studies assessing the incidence and mortality of QT-interval prolongation, Torsades de Pointes, and heart failure in patients with NSCLC treated with EGFR TKIs.

bit.ly/43VrQD3

Can radiomics help predict outcomes after neoadjuvant chemotherapy?

Check out a new article titled 'Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for NSCLC: A Retrospective Study'

bit.ly/49y49Ce

According to the Danish Lung Cancer Registry, the risk of venous thromboembolism (VTE) is < 6% for stage IIIA and to up to 12.5% in stage IV.

The risk of VTE varies by stage and treatment of NSCLC, with the highest risk during the first six months.

bit.ly/43TQIv0

Real-world outcomes with neoadjuvant chemotherapy or chemoradiation for resectable stage II-III NSCLC Clinical Lung Cancer from Dr. donington et al. rwEFS 17.6m, 5y rwEFS 21%, 71% with recurrence in follow up. Expect better with immunotherapy.

clinical-lung-cancer.com/article/S1525-…

Efficacy of EGFR-TKI therapy in patients with metastatic EGFR-mutant NSCLC and poor performance status: Findings from the Japanese Lung Cancer Registry Database

Full article: bit.ly/3IOqrV5

Primary pulmonary lymphoepithelial carcinoma (LEC) is a rare form of lung cancer, often associated with Epstein Barr virus (EBV)

Explore a case report discussing the use of neoadjuvant chemoimmunotherapy prior to the resection of primary pulmonary LEC

bit.ly/3Tu0kYG

An analysis of US electronic health records on the clinical characteristics, treatment patterns, and outcomes of patients with HER2-mutant advanced NSCLC diagnosed between 2016 and 2020

Link to the full article: bit.ly/3vnimnq

ETV6-NTRK2 fusion in a patient with metastatic pulmonary atypical carcinoid successfully treated with entrectinib: A case report and review of the literature

bit.ly/3TxE28s

Update on efficacy of POSEIDON (first-line durvalumab +/- tremelimumab + chemotherapy vs chemo in NSCLC) by PD-L1 strata Clinical Lung Cancer. Durva + treme + chemo improved OS for both PD-L1 ≥1% (HR 0.76) and PD-L1 negative (HR 0.77). FDA approved 11/10/22.

clinical-lung-cancer.com/article/S1525-…